Alaunos Therapeutics Inc (FRA:WEK)
€ 1.41 0 (0%) Market Cap: 326.90 Mil Enterprise Value: 325.71 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 55/100

Q3 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

Nov 08, 2021 / 09:30PM GMT
Operator

Greetings. Welcome to the Ziopharm Oncology Third Quarter 2021 Earnings Conference Call. (Operator Instructions)

Please note, this conference is being recorded. I will now turn the conference over to your host, Alex Lobo, Stern Investor Relations. Thank you. You may begin.

Alex Lobo

Thank you. Good afternoon, and welcome to Ziopharm Oncology's Third Quarter 2021 Financial Results Conference Call and Audio Webcast. With me today are Kevin Boyle Senior, Ziopharm's Chief Executive Officer; and Raffaele Baffa, Ziopharm's Chief Medical Officer and Executive Vice President of Research and Development.

Earlier this afternoon, Ziopharm issued a press release announcing financial results for the 3 months ended September 30, 2021. We encourage everyone to read today's press release as well as Ziopharm's quarterly report on Form 10-Q for the third quarter 2021, which has been filed with the SEC. The company's press release and quarterly report will also be available on Ziopharm's website at ziopharm.com. In addition, this conference call is being webcast

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot